SF3B1 and cancer: However, although preclinical studies with currently available SF3b‐targeting compounds have shown that these are more toxic to cancer cells than to healthy cells, we found that silencing the expression of SF3B1 and SF3B6 proteins also caused considerable toxicity in nonmalignant IMR‐90 fibroblasts.